Financial Calendar Unveiled for PHAXIAM Therapeutics
PHAXIAM Therapeutics (Euronext: PHXM), a pioneering biopharmaceutical entity dedicated to creating innovative solutions for severe bacterial infections, has announced its financial calendar for the upcoming year, 2025. This schedule marks significant milestones for the company as it continues to advance its groundbreaking research and treatments in an area of critical health importance.
Upcoming Key Dates
The financial calendar outlines essential company events designed to keep investors informed about its progress:
March 2025: Business Update
On March 13, 2025, after the closing of the stock market, PHAXIAM will release its updated business metrics along with the complete financial results for 2024. Following this, a webinar will be hosted in French, allowing stakeholders an opportunity to discuss the results and future directions at 6:00 PM CET.
Annual General Meeting in June 2025
In June, specifically on the 24th, PHAXIAM will hold its Annual General Meeting. This gathering serves as a platform for shareholders to engage with the company's leadership, review the past year, and deliberate on the future.
September 2025: Mid-Year Report
Another scheduled event will occur on September 24, 2025, which will provide insights into the company's performance for the first half of the year. The financial release will again be followed by a French-language webinar at 6:00 PM CET, targeting local and interested investors.
About PHAXIAM Therapeutics
PHAXIAM Therapeutics is committed to developing transformative therapies for resistant bacterial infections, which pose significant health risks worldwide. The company focuses on an innovative methodology utilizing phages—viruses that specifically target bacteria. This approach addresses three of the most formidable and resistant pathogens recognized today: Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, which collectively account for a substantial portion of hospital-acquired infections.
PHAXIAM Therapeutics is currently listed on the Euronext regulated market in Paris under the ISIN code: FR0011471135, with the stock ticker PHXM. The company is a recognized member of several notable indices including the CAC Healthcare, CAC Pharma & Bio, and Next Biotech indexes—highlighting its significance within the biotech sector.
Research and Development Focus
The research teams at PHAXIAM are diligently working on a portfolio of phages aimed specifically at combatting resistant infections. By leveraging the natural capabilities of these bacterial-killing viruses, PHAXIAM hopes to make strides in a field that has seen very few breakthroughs in recent years.
As antibiotic resistance becomes an increasingly grave concern worldwide, the initiatives undertaken by PHAXIAM may turn out to be pivotal in reshaping the landscape of infectious disease treatment. Their commitment to innovative approaches will no doubt resonate with healthcare professionals and investors alike.
Forward-Looking Statements
It is important to note that while the provided information concerning PHAXIAM's activities and future prospects is based on reasonable assumptions, actual developments may vary significantly due to various risk factors and uncertainties inherent in biopharmaceutical research and development. Stakeholders are encouraged to keep an eye on regulatory filings and updates from the company, particularly regarding the evolving landscape of its clinical programs.
Frequently Asked Questions
What is the financial calendar for PHAXIAM Therapeutics in 2025?
The calendar includes significant events like the March update on business, the Annual General Meeting in June, and September's half-year financial results presentation.
Where is PHAXIAM Therapeutics listed?
PHAXIAM is listed on the Euronext regulated market in Paris, under ISIN code: FR0011471135 and ticker symbol PHXM.
What innovative approach does PHAXIAM Therapeutics focus on?
PHAXIAM concentrates on developing treatments using phages, which are natural viruses capable of targeting and killing bacteria.
Who are the primary bacterial targets for PHAXIAM's therapies?
The company is developing phage therapies aimed at Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
Can investors participate in the webinars mentioned in the financial calendar?
Yes, the webinars following financial updates will be available for stakeholders to participate and discuss outcomes in greater detail.
